Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 4/20 | 0.70 |
| ▸ | HTR1A | P08908 | 4/20 | 0.70 |
| ▸ | HTR2A | P28223 | 3/20 | 0.70 |
| ▸ | HTR2C | P28335 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.69 |
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.69 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.69 |
| ▸ | LTA4H | P09960 | 1/20 | 0.69 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.68 |
| ▸ | BLM | P54132 | 4/20 | 0.68 |
| ▸ | PMP22 | Q01453 | 4/20 | 0.68 |
| ▸ | MAPT | P10636 | 3/20 | 0.68 |
| ▸ | TSHR | P16473 | 3/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.68 |
| ▸ | HTR7 | P34969 | 2/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1421284 | 1.00 | HTR2B (0.70) | HTR2BHTR1AHTR2AHTR2CKMT2A | |
| SCHEMBL18029115 | 1.00 | HTR2B (0.70) | HTR2BHTR1AHTR2AHTR2CKMT2A | |
| SCHEMBL122600 | 1.00 | HTR2B (0.70) | HTR2BHTR1AHTR2AHTR2CKMT2A | |
| SCHEMBL2330863 | 1.00 | HTR2B (0.70) | HTR2BHTR1AHTR2AHTR2CKMT2A | |
| Ammonia Solution, Strong SCHEMBL28594768 | 0.99 | HTR2B (0.68) | HTR2BHTR1AHTR2AHTR2CKMT2A | |
| SCHEMBL1460676 | 0.90 | KMT2A (0.61) | HTR2BHTR1AHTR2AHTR2CKMT2A | |
| SCHEMBL18029114 | 0.90 | KMT2A (0.61) | HTR2BHTR1AHTR2AHTR2CKMT2A | |
| SCHEMBL1460679 | 0.90 | KMT2A (0.61) | HTR2BHTR1AHTR2AHTR2CKMT2A | |
| SCHEMBL31370348 | 0.90 | KMT2A (0.61) | HTR2BHTR1AHTR2AHTR2CKMT2A | |
| SCHEMBL1607394 | 0.90 | HTR2B (0.70) | HTR2BHTR1AHTR2AHTR2CKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1754 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727655-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | Mariana Oncology Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4727654-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | Mariana Oncology Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | claimed |
| EP-3746467-B1 | MODIFIED LIPIDATED RELAXIN B CHAIN PEPTIDES AND THEIR THERAPEUTIC USE | SANOFI SA (FR) | 2025-10-08 | — | — | EP | claimed |
| US-12415834-B2 | GhR-binding peptide and composition comprising same | PEPTIDREAM INC. (JP) | 2025-09-16 | — | — | US | claimed |
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2025-07-08 | — | — | US | claimed |
| US-20250049970-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | MARIANA ONCOLOGY INC (US) | 2025-02-13 | — | — | US | claimed |
| US-12203115-B2 | Universal platform for genetic code expansion | TRUSTEES OF BOSTON COLLEGE (US) | 2025-01-21 | — | — | US | claimed |
| US-20250011368-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | MARIANA ONCOLOGY INC (US) | 2025-01-09 | — | — | US | claimed |
| WO-2024259115-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | MARIANA ONCOLOGY INC. (US) | 2024-12-19 | — | — | WO | claimed |
| EP-0820766-A2 | New topical compositions containing very low doses of melatonin or derivatives thereof and their use in cosmetics | L'OREAL (FR) | 1998-01-28 | — | — | EP | claimed |
| EP-0736770-A2 | An immunoreactive conjugate, method for its preparation, antibodies to said conjugate and a pharmaceutical composition and diagnostic device containing them | ANDA BIOLOGICALS S.A. (FR) | 1996-10-09 | — | — | EP | claimed |
| EP-0214254-B1 | MELATONIN COMPOSITIONS AND USES THEREOF | CELLENA (CELL ENGINEERING) A.G. (CH) | 1992-06-17 | — | — | EP | claimed |
| US-4762781-A | COUPLED TO AMINE OR GUANIDINE GROUPS OF HAPTENS VIA REACTION WITH DIALDEHYDE, IMMUNOLOGY | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1988-08-09 | — | — | US | claimed |
| US-4746674-A | Melatonin compositions and uses thereof | CELLENA (CELL ENGINEERING) AG (CH) | 1988-05-24 | — | — | US | claimed |
| EP-0229131-A1 | USE OF MELATONIN OR RELATED COMPOUNDS FOR THE TREATMENT OF PSORIASIS | CELLENA (CELL ENGENEERING) A.G. (CH) | 1987-07-22 | — | — | EP | claimed |
| WO-1987000432-A2 | USE OF MELATONIN OR RELATED COMPOUNDS FOR THE TREATMENT OF PSORIASIS | CELLENA (CELL ENGINEERING) A.G. (CH) | 1987-01-29 | — | — | WO | claimed |
| EP-0149405-A2 | Antibodies capable of specifically recognizing haptenic groups, their preparation and application, and antigens for the preparation of these antibodies | Etablissement Public dit: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1985-07-24 | — | — | EP | claimed |
| US-3963572-A | Fermentative process for the production of L-tryptophan and its derivatives | AB BOFORS (SW) | 1976-06-15 | — | — | US | claimed |
| US-3930948-A | ENZYMATIC METHOD FOR PRODUCING AROMATIC ETHYLAMINES | AJINOMOTO CO., INC. (JA) | 1976-01-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | DNPEP, NPEPPS, PAM | HTR2B 2179/4885HTR1A 3830/4885HTR2A 3159/4885 |
| US-12415834-B2 | GhR-binding peptide and composition comprising same | GHRHR, GHSR, GIPR | HTR2B 1337/4885HTR1A 1979/4885HTR2A 1926/4885 |
| US-20250049970-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | DLK1, DBNL, PDLIM5 | HTR2B 4864/4885HTR1A 4862/4885HTR2A 4848/4885 |
| US-20250011368-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | DLK1, DBNL, PDCD1LG2 | HTR2B 4862/4885HTR1A 4863/4885HTR2A 4847/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | HTR2B 346/4885HTR1A 801/4885HTR2A 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.